• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

1998 Fiscal Year Final Research Report Summary

Radiopharmaceuticals that liberate radiometabolites of urinary excretion by renal brush border enzymes

Research Project

Project/Area Number 09672279
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field 医薬分子機能学
Research InstitutionKYOTO UNIVERSITY

Principal Investigator

ARANO Yasushi  Kyoto University, Graduate School of Pharmaceutical Sciences, Associate Professor, 薬学研究科, 助教授 (90151167)

Project Period (FY) 1997 – 1998
KeywordsAntiby fragments / Metabilizable linkage / Targeted imaging / Radiotherapy / Radiopharmaceuticals / Radiometabilites / Brush border enzymes / Renal accumulation
Research Abstract

The renal uptake of radiolabeled low molecular weight (LMW) polypeptides presents a problem in targeted imaging and therapy. We hypothesized that the renal radioactivity levels of radiolabeled LMW polypeptides could be reduced if radiolabeled compounds of urinary excretion are released from glomerularly-filtered polypeptides before they are incorporated into renal cells by the action of brush border enzymes present on the lumen of renal tubules. 3'-[^<131>I]Iodohippuryl N^<epsilon>-maleoyl-L-lysine ([^<131>I]HML) was conjugated with a thiolated Fab fragment, since the glycyl-lysine sequence in HML is a substrate for a brush border enzyme. Fab fragments were also radiolabeled by direct radioiodination (^<125>I-Fab) or by conjugation with meta-[^<125>I]iodohippuric acid via an amide bond ([^<125>I]MPH-Fab) or an ester bond ([^<125>I]MIH-Fab) by similar procedures. When injected into mice, [^<131>I]HML-Fab demonstrated markedly low renal radioactivity levels with kidney-to-blood ratios of … More radioactivity of i from 10 min to i h due to rapid release of meta-[^<131>I]iodohippuric acid. [^<125>I]MIH-Fab and ^<125>I-Fab reached their peak ratios of 3.8 and 7.3 at 1 h, and [^<125>I]MPH-Fab showed the maximum ratio of 16.8 at 6 h. In subcellular distribution studies, both [^<125>I]MIH-Fab and ^<125>I-Fab showed radioactivity migration from the membrane to the lysosomal fraction of the renal cells from 10 to 30 min postinjection, whereas the majority of the radioactivity was detected only in the membrane fraction after administration of [^<131>I]HML-Fab at both time points. In nude mice, [^<131>I]HML-Fab showed one quarter of renal radioactivity of ^<125>I-Fab without impairing the target radioactivity levels 3 h after injection. These findings indicated that HML is a useful reagent for targeted imaging and therapy using antibody fragments as vehicles. These findings also suggested that the design of radiolabeled LMW polypeptides that liberate radiometabolites of urinary excretion by the action of brush border enzymes may constitute a new strategy for reducing the renal radioactivity levels of LMW polypeptides. Less

  • Research Products

    (16 results)

All Other

All Publications (16 results)

  • [Publications] K., Wakisaka: "A Novel Radioiodination Reagent for Protein Radiopharmaceuticals with L-Lysine as pa Plasma-Stable Metabolizable Linkage to Liberate meta-Iodohippuric Acid after Lysosomal Proteolysis." Joranal of Medicinal Chemistry. 40,16. 2643-2652 (1997)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] L., C.Xu: "Synthesis and Evaluation of Hydroxamamide-Based Tetradentate Ligands as a New Class of Thiol Free Chelating molecules for ^<99m>Tc Radiopharmaceuticals." Nuclear Medicine and Biology. 25,3. 295-303 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Y.,Arano: "Assessment of the Radiochemical Design of Antibodies with a Metabolizable Linkage for Target-Selective Radioactivity Delivery." Bioconjugate Chemistry. 9,4. 497-506 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] H., Akizawa: "Renal Metabolism of ^<111>In-DTPA-D-Phe^1-Octreotide In Vivo." Bioconjugate Chemistry. 9,6. 662-670 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Y,Arano: "Strategies to Renal Radioactivity Levels of Antibody Fragments." Quarterly Journal of Nuclear Medicine. 42,4. 262-270 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Y,Arano: "Chemical Design of Antibody Fragments for Low Renal Radioactivity Levels." Cancer Research. 59,1. 128-134 (1999)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Y,Arano: "Synthesis and Applications of Isotopically Labelled Compounds 1997." R.L.Heys and D.G.Melillo eds., John Wiley & Sons, Chichester, UK., 307-310 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Y., Arano: "Technetium in Chemistry and Nuclear Medicine" Nicolini M.and Mazzi U.eds., Edizion Minerva Medica, Corso Bramante, Italy., 印刷中 (1999)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] K.Wakisaka, et al.: "A Novel Radioiodination Reagent for Protein Radiopharmaceuticals with L-Lysine as a Plasma-Stable Metabolizable Linkage to Liberate meta-Iodohippuric Acid after Lysosomal Proteolysis." J.Med.Chem.40(16). 2643-2652 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] L.C.Xu, et al.: "Synthesis and Evaluation of Hydroxamamide-Based Tetradentate Ligands as a New Class of Thiol Free Chelating molecules for ^<99m>Tc Radiopharmaceuticals." Nucl.Med.Biol.25(3). 295-303 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Y.Arano, et al.: "Assessment of the Radiochemical Design of Antibodies with a Metabolizable Linkage for Target-Selective Radioactivity Delivery." Bioconjugate Chem.9(4). 497-506 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] H.Akizawa, et al.: "Renal Metabolism of ^<111>In-DTPA-D-Phe^1-Octreotide In Vivo" Bioconjugate Chem.9(6). 662-670 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Y.Arano.: "Strategies to Reduce Renal Radioactivity Levels of Antibody Fragments.(Review)" Q.J.Nucl.Med.42(4). 262-270 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Y.Arano, et al.: "Chemical Design of Antibody Framents for Low Renal Radioactivity Levels." Cancer Res. 59(1). 128-134 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Y.Arano, et al.: "Synthesis and Applications of Isotopically Labelled Compounds 1997." John Wiley & Sons, Chichester, UK.307-310 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Y.Arano, et al.: "Technetium in Chemistry and Nuclear Medicine." Edizion Minerva Medica, Corso Bramante, Italy.(in press).

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 1999-12-08  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi